CAM-话题@MedSci - williamhill asia

#CAM#

107篇内容 | 1916人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1675394, encodeId=2c9316e5394c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=JAMA：陈会生教授团队发现远隔缺血适应能改善急性中度缺血性卒中患者功能预后（RICAMIS研究）, objectType=article, longId=736132, objectId=4dc4e36132fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dc4e36132fd, replyNumber=0, likeNumber=91, createdTime=2022-11-11, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dc4e36132fd, moduleTitle=JAMA：陈会生教授团队发现远隔缺血适应能改善急性中度缺血性卒中患者功能预后（RICAMIS研究）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4dc4e36132fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675389, encodeId=deb216e538971, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=联拓生物完成Mavacamten在中国健康志愿者中的I期药代动力学研究, objectType=article, longId=726512, objectId=5008e26512f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5008e26512f9, replyNumber=0, likeNumber=79, createdTime=2023-01-02, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5008e26512f9, moduleTitle=联拓生物完成Mavacamten在中国健康志愿者中的I期药代动力学研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5008e26512f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675387, encodeId=092316e5387c1, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Evid Based Complement Alternat Med：越鞠丸持续的抗抑郁活性——海马CaMKII信号的参与, objectType=article, longId=302175, objectId=840f3021e5b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=840f3021e5b5, replyNumber=0, likeNumber=90, createdTime=2022-08-15, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=840f3021e5b5, moduleTitle=Evid Based Complement Alternat Med：越鞠丸持续的抗抑郁活性——海马CaMKII信号的参与, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=840f3021e5b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675390, encodeId=806d16e53909d, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=新一代心肌肌球蛋白抑制剂aficamten在中国获得3期临床试验申请批准，用于治疗症状性梗阻性肥厚型心肌病, objectType=article, longId=730815, objectId=f09be30815b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f09be30815b3, replyNumber=0, likeNumber=91, createdTime=2023-05-15, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f09be30815b3, moduleTitle=新一代心肌肌球蛋白抑制剂aficamten在中国获得3期临床试验申请批准，用于治疗症状性梗阻性肥厚型心肌病, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f09be30815b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675395, encodeId=6c4e16e5395f5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, objectType=article, longId=739077, objectId=6949e390775b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6949e390775b, replyNumber=0, likeNumber=102, createdTime=2023-04-08, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6949e390775b, moduleTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6949e390775b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675392, encodeId=e6a916e539266, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=首个直接注入大脑的基因疗法上市；血友病AAV基因疗法临床试验效果显著；CAMP4融资1亿美元推进ASO疗法进入临床, objectType=article, longId=732968, objectId=eb91e3296844, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb91e3296844, replyNumber=0, likeNumber=81, createdTime=2022-08-30, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb91e3296844, moduleTitle=首个直接注入大脑的基因疗法上市；血友病AAV基因疗法临床试验效果显著；CAMP4融资1亿美元推进ASO疗法进入临床, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=eb91e3296844)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675378, encodeId=479816e53781c, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, objectType=article, longId=221101, objectId=e69e221101af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69e221101af, replyNumber=0, likeNumber=90, createdTime=2022-05-24, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69e221101af, moduleTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e69e221101af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675391, encodeId=aacd16e539175, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=EBCAM：罗哌卡因和利多卡因在双眼皮整形术中有何不同？, objectType=article, longId=730451, objectId=0d2ee3045112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d2ee3045112, replyNumber=0, likeNumber=68, createdTime=2022-09-12, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d2ee3045112, moduleTitle=EBCAM：罗哌卡因和利多卡因在双眼皮整形术中有何不同？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0d2ee3045112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675380, encodeId=38ef16e53808e, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=EBCAM:隔姜灸、温和灸和激光灸对腹泻型肠易激综合征大鼠的疗效比较, objectType=article, longId=221695, objectId=c13e22169589, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c13e22169589, replyNumber=0, likeNumber=93, createdTime=2022-09-30, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c13e22169589, moduleTitle=EBCAM:隔姜灸、温和灸和激光灸对腹泻型肠易激综合征大鼠的疗效比较, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c13e22169589)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675388, encodeId=4e6716e538829, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准, objectType=article, longId=725731, objectId=7110e25731dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7110e25731dc, replyNumber=0, likeNumber=89, createdTime=2022-07-14, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7110e25731dc, moduleTitle=肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7110e25731dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675393, encodeId=e3e216e5393f5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募, objectType=article, longId=735587, objectId=f431e3558751, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f431e3558751, replyNumber=0, likeNumber=80, createdTime=2022-09-21, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f431e3558751, moduleTitle=联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f431e3558751)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675379, encodeId=127e16e5379a0, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=EBCAM:六味地黄丸联合糖皮质激素治疗儿童原发性肾病综合征的疗效观察, objectType=article, longId=221584, objectId=e68c2215840a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e68c2215840a, replyNumber=0, likeNumber=85, createdTime=2022-04-03, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e68c2215840a, moduleTitle=EBCAM:六味地黄丸联合糖皮质激素治疗儿童原发性肾病综合征的疗效观察, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e68c2215840a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675377, encodeId=977e16e53772d, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=EBCAM:基于网络药理学的黄芪四君子汤治疗阿尔茨海默病机制研究, objectType=article, longId=219026, objectId=a3772190266c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3772190266c, replyNumber=0, likeNumber=71, createdTime=2022-05-18, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3772190266c, moduleTitle=EBCAM:基于网络药理学的黄芪四君子汤治疗阿尔茨海默病机制研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a3772190266c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675384, encodeId=6bd916e53849e, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Mavacamten获中国“突破性治疗药物”认证，用于治疗梗阻性肥厚型心肌病, objectType=article, longId=298944, objectId=f5d829894405, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d829894405, replyNumber=0, likeNumber=70, createdTime=2022-12-16, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d829894405, moduleTitle=Mavacamten获中国“突破性治疗药物”认证，用于治疗梗阻性肥厚型心肌病, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f5d829894405)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675382, encodeId=f1e316e538243, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=EBCAM：加味滋肾通管汤配合针刺治疗宫颈癌术后尿潴留的疗效观察, objectType=article, longId=292944, objectId=de752929442c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de752929442c, replyNumber=0, likeNumber=67, createdTime=2022-03-19, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de752929442c, moduleTitle=EBCAM：加味滋肾通管汤配合针刺治疗宫颈癌术后尿潴留的疗效观察, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=de752929442c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675383, encodeId=17c016e5383d2, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=EXPLORER-CN 3期临床试验：Mavacamten治疗有症状的梗阻性肥厚型心肌病在中国完成首例患者给药, objectType=article, longId=293854, objectId=d952293854cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d952293854cb, replyNumber=0, likeNumber=68, createdTime=2022-07-14, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d952293854cb, moduleTitle=EXPLORER-CN 3期临床试验：Mavacamten治疗有症状的梗阻性肥厚型心肌病在中国完成首例患者给药, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d952293854cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675376, encodeId=79b716e5376d4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=CELL：CaMKII 的重新激活可保护视神经细胞以防止青光眼视力丧失, objectType=article, longId=214854, objectId=a54c21485499, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a54c21485499, replyNumber=0, likeNumber=84, createdTime=2021-11-11, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a54c21485499, moduleTitle=CELL：CaMKII 的重新激活可保护视神经细胞以防止青光眼视力丧失, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a54c21485499)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675386, encodeId=65c316e538694, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Cancer Immunol Immunother：Camrelizumab（卡瑞利珠单抗）联合阿帕替尼和S1作为二线治疗晚期胃或胃食管交界处腺癌的疗效, objectType=article, longId=301252, objectId=1d863012523c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d863012523c, replyNumber=0, likeNumber=76, createdTime=2022-06-12, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d863012523c, moduleTitle=Cancer Immunol Immunother：Camrelizumab（卡瑞利珠单抗）联合阿帕替尼和S1作为二线治疗晚期胃或胃食管交界处腺癌的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1d863012523c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675381, encodeId=301516e538182, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, objectType=article, longId=292765, objectId=7f53292e6591, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f53292e6591, replyNumber=0, likeNumber=84, createdTime=2022-12-08, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f53292e6591, moduleTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7f53292e6591)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675385, encodeId=035116e538526, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=实验性心脏肌球蛋白激活剂omecamtiv mecarbil在心衰患者中对运动能力没有任何益处, objectType=article, longId=299004, objectId=752f2990048e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=752f2990048e, replyNumber=0, likeNumber=96, createdTime=2022-10-15, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=752f2990048e, moduleTitle=实验性心脏肌球蛋白激活剂omecamtiv mecarbil在心衰患者中对运动能力没有任何益处, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=752f2990048e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

CAM

2020-05-29

whmdzju (审核中...)

前往app查看评论内容

#CAM#

JAMA：陈会生教授团队发现远隔缺血适应能改善急性中度缺血性卒中患者功能预后（RICAMIS研究）

2022-11-11

whmdzju (审核中...)

前往app查看评论内容

#CAM#

联拓生物完成Mavacamten在中国健康志愿者中的I期药代动力学研究

2023-01-02

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Evid Based Complement Alternat Med：越鞠丸持续的抗抑郁活性——海马CaMKII信号的参与

2022-08-15

whmdzju (审核中...)

前往app查看评论内容

#CAM#

新一代心肌肌球蛋白抑制剂aficamten在中国获得3期临床试验申请批准，用于治疗症状性梗阻性肥厚型心肌病

2023-05-15

whmdzju (审核中...)

前往app查看评论内容

#CAM#

ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）

2023-04-08

whmdzju (审核中...)

前往app查看评论内容

#CAM#

首个直接注入大脑的基因疗法上市；血友病AAV基因疗法临床试验效果显著；CAMP4融资1亿美元推进ASO疗法进入临床

2022-08-30

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性

2022-05-24

whmdzju (审核中...)

前往app查看评论内容

#CAM#

EBCAM：罗哌卡因和利多卡因在双眼皮整形术中有何不同？

2022-09-12

whmdzju (审核中...)

前往app查看评论内容

#CAM#

EBCAM:隔姜灸、温和灸和激光灸对腹泻型肠易激综合征大鼠的疗效比较

2022-09-30

whmdzju (审核中...)

前往app查看评论内容

#CAM#

肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准

2022-07-14

whmdzju (审核中...)

前往app查看评论内容

#CAM#

联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募

2022-09-21

whmdzju (审核中...)

前往app查看评论内容

#CAM#

EBCAM:六味地黄丸联合糖皮质激素治疗儿童原发性肾病综合征的疗效观察

2022-04-03

whmdzju (审核中...)

前往app查看评论内容

#CAM#

EBCAM:基于网络药理学的黄芪四君子汤治疗阿尔茨海默病机制研究

2022-05-18

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Mavacamten获中国“突破性治疗药物”认证，用于治疗梗阻性肥厚型心肌病

2022-12-16

whmdzju (审核中...)

前往app查看评论内容

#CAM#

EBCAM：加味滋肾通管汤配合针刺治疗宫颈癌术后尿潴留的疗效观察

2022-03-19

whmdzju (审核中...)

前往app查看评论内容

#CAM#

EXPLORER-CN 3期临床试验：Mavacamten治疗有症状的梗阻性肥厚型心肌病在中国完成首例患者给药

2022-07-14

whmdzju (审核中...)

前往app查看评论内容

#CAM#

CELL：CaMKII 的重新激活可保护视神经细胞以防止青光眼视力丧失

2021-11-11

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Cancer Immunol Immunother：Camrelizumab（卡瑞利珠单抗）联合阿帕替尼和S1作为二线治疗晚期胃或胃食管交界处腺癌的疗效

2022-06-12

whmdzju (审核中...)

前往app查看评论内容

#CAM#

J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著

2022-12-08

whmdzju (审核中...)

前往app查看评论内容

#CAM#

实验性心脏肌球蛋白激活剂omecamtiv mecarbil在心衰患者中对运动能力没有任何益处

2022-10-15

科室
- - 订阅+
  - 更多科室
工具
服务